Belgian medtech company Xeos has raised 14 million euros ($16.3 million) in a financing round backed by a group of Flanders-based healthcare technology investors.
The funds will be used to accelerate commercial expansion of the company’s AURA 10 PET-CT platform in the European Union and U.S., as well as to bolster clinical and health-economic evidence supporting the system, the firm said. In addition, the funds will be used to build a network of reference centers to strengthen Xeos’ clinical collaboration and visibility.
AURA 10 PET-CT is the first intraoperative specimen PET-CT system, according to Xeos. The platform enables the acquisition of a high-resolution, three-dimensional molecular image of resected tissue while the patient remains under anesthesia, providing immediate feedback during surgery.
It also generates a growing dataset for the development of AI-based image analysis tools, Xeos said, noting that it has recently published results demonstrating that deep-learning models can automatically evaluate breast tumor images with accuracy comparable to that of expert assessment.
The platform is currently in use in the U.S. and seven European countries and has been used in more than 500 patient procedures across a range of oncologic indications, Xeos added.
